Literature DB >> 19355929

Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.

David H Cribbs, Michael G Agadjanyan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19355929     DOI： 10.2174/187152709787847270

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN： 1871-5273            Impact factor:   4.388


× No keyword cloud information.
  3 in total

1.  DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.

Authors:  H Davtyan; M Mkrtichyan; N Movsesyan; I Petrushina; G Mamikonyan; D H Cribbs; M G Agadjanyan; A Ghochikyan
Journal:  Gene Ther       Date:  2009-10-29       Impact factor: 5.250

2.  The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease.

Authors:  Hayk Davtyan; Anahit Ghochikyan; Richard Cadagan; Dmitriy Zamarin; Irina Petrushina; Nina Movsesyan; Luis Martinez-Sobrido; Randy A Albrecht; Adolfo García-Sastre; Michael G Agadjanyan
Journal:  J Transl Med       Date:  2011-08-01       Impact factor: 5.531

3.  Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease.

Authors:  Roxana Octavia Carare; Jessica Liesbeth Teeling; Cheryl A Hawkes; Ursula Püntener; Roy O Weller; James A R Nicoll; Victor Hugh Perry
Journal:  Acta Neuropathol Commun       Date:  2013-08-09       Impact factor: 7.801
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.